288 related articles for article (PubMed ID: 28297583)
1. Assessment of Drug Sensitivity in Hematopoietic Stem and Progenitor Cells from Acute Myelogenous Leukemia and Myelodysplastic Syndrome Ex Vivo.
Knorr KL; Finn LE; Smith BD; Hess AD; Foran JM; Karp JE; Kaufmann SH
Stem Cells Transl Med; 2017 Mar; 6(3):840-850. PubMed ID: 28297583
[TBL] [Abstract][Full Text] [Related]
2. The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR.
Zhou L; Chen S; Zhang Y; Kmieciak M; Leng Y; Li L; Lin H; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Rahmani M; Povirk L; Chalasani S; Berger AJ; Dai Y; Grant S
Blood; 2016 May; 127(18):2219-30. PubMed ID: 26851293
[TBL] [Abstract][Full Text] [Related]
3. Asia-inclusive global development of pevonedistat: Clinical pharmacology and translational research enabling a phase 3 multiregional clinical trial.
Zhou X; Friedlander S; Kupperman E; Sedarati F; Kuroda S; Hua Z; Yuan Y; Yamamoto Y; Faller DV; Haikawa K; Nakai K; Bowen S; Dai Y; Venkatakrishnan K
Clin Transl Sci; 2021 May; 14(3):1069-1081. PubMed ID: 33503305
[TBL] [Abstract][Full Text] [Related]
4. Perturbed hematopoietic stem and progenitor cell hierarchy in myelodysplastic syndromes patients with monosomy 7 as the sole cytogenetic abnormality.
Dimitriou M; Woll PS; Mortera-Blanco T; Karimi M; Wedge DC; Doolittle H; Douagi I; Papaemmanuil E; Jacobsen SE; Hellström-Lindberg E
Oncotarget; 2016 Nov; 7(45):72685-72698. PubMed ID: 27683035
[TBL] [Abstract][Full Text] [Related]
5. Effect of chemotherapy for acute myelogenous leukemia on hematopoietic and fibroblast marrow progenitors.
Carlo-Stella C; Tabilio A; Regazzi E; Garau D; La Tagliata R; Trasarti S; Andrizzi C; Vignetti M; Meloni G
Bone Marrow Transplant; 1997 Sep; 20(6):465-71. PubMed ID: 9313879
[TBL] [Abstract][Full Text] [Related]
6. [Cytogenetic characteristics of hematopoietic and stromal progenitor cells in myelodysplastic syndrome].
Pimenova MA; Parovichnikova EN; Kokhno AV; Domracheva EV; Manakova TE; Mal'tseva IuS; Konnova ML; Shishigina LA; Savchenko VG
Ter Arkh; 2013; 85(7):34-42. PubMed ID: 24137945
[TBL] [Abstract][Full Text] [Related]
7. Differential responses of myeloid progenitor cells from patients with myeloid leukemia and myelodysplasia to the costimulating effects of steel factor in vitro.
Maze R; Horie M; Hendrie P; Vadhan-Raj S; Tricot G; Gordon M; Nemunaitis J; Ashman LK; Broxmeyer HE
Exp Hematol; 1993 Apr; 21(4):545-51. PubMed ID: 7681784
[TBL] [Abstract][Full Text] [Related]
8. Thrombopoietin stimulates myelodysplastic syndrome granulocyte-macrophage and erythroid progenitor proliferation.
Ferrajoli A; Talpaz M; Kurzrock R; Harris D; Van Q; Estey EH; Estrov Z
Leuk Lymphoma; 1998 Jul; 30(3-4):279-92. PubMed ID: 9713960
[TBL] [Abstract][Full Text] [Related]
9. Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines.
Liesveld JL; Rosell KE; Bechelli J; Lu C; Messina P; Mulford D; Ifthikharuddin JJ; Jordan CT; Phillips Ii GL
Cancer Invest; 2011 Aug; 29(7):439-50. PubMed ID: 21740082
[TBL] [Abstract][Full Text] [Related]
10. A Study of Human Leukocyte Antigen Mismatched Cellular Therapy (Stem Cell Microtransplantation) in High-Risk Myelodysplastic Syndrome or Transformed Acute Myelogenous Leukemia.
Hu KX; Sun QY; Guo M; Qiao JX; Yu CL; Qiao JH; Dong Z; Sun WJ; Zuo HL; Huang YJ; Cai B; Ai HS
Stem Cells Transl Med; 2016 Apr; 5(4):524-9. PubMed ID: 26838271
[TBL] [Abstract][Full Text] [Related]
11. Do preclinical studies suggest that CD99 is a potential therapeutic target in acute myeloid leukemia and the myelodysplastic syndromes?
Tavakkoli M; Chung SS; Park CY
Expert Opin Ther Targets; 2018 May; 22(5):381-383. PubMed ID: 29637789
[TBL] [Abstract][Full Text] [Related]
12. Granulomonocytic progenitors are key target cells of azacytidine in higher risk myelodysplastic syndromes and acute myeloid leukemia.
Ali A; Penneroux J; Dal Bello R; Massé A; Quentin S; Unnikrishnan A; Hernandez L; Raffoux E; Ben Abdelali R; Renneville A; Preudhomme C; Pimanda J; Dombret H; Soulier J; Fenaux P; Clappier E; Adès L; Puissant A; Itzykson R
Leukemia; 2018 Aug; 32(8):1856-1860. PubMed ID: 29535430
[No Abstract] [Full Text] [Related]
13. The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34
Mani R; Goswami S; Gopalakrishnan B; Ramaswamy R; Wasmuth R; Tran M; Mo X; Gordon A; Bucci D; Lucas DM; Mims A; Brooks C; Dorrance A; Walker A; Blum W; Byrd JC; Lozanski G; Vasu S; Muthusamy N
Haematologica; 2018 Aug; 103(8):1288-1297. PubMed ID: 29773600
[TBL] [Abstract][Full Text] [Related]
14. Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome.
Wu L; Li X; Su J; Chang C; He Q; Zhang X; Xu L; Song L; Pu Q
Leuk Lymphoma; 2009 Sep; 50(9):1461-7. PubMed ID: 19672772
[TBL] [Abstract][Full Text] [Related]
15. Bone marrow cellularity in myeloid stem cell disorders: impact of age correction.
Tuzuner N; Cox C; Rowe JM; Bennett JM
Leuk Res; 1994 Aug; 18(8):559-64. PubMed ID: 8065157
[TBL] [Abstract][Full Text] [Related]
16. Myelodysplastic neoplasms dissected into indolent, leukaemic and unfavourable subtypes by computational clustering of haematopoietic stem and progenitor cells.
van Spronsen MF; Van Gassen S; Duetz C; Westers TM; Saeys Y; van de Loosdrecht AA
Leukemia; 2024 Jun; 38(6):1365-1377. PubMed ID: 38459168
[TBL] [Abstract][Full Text] [Related]
17. Novel inhibitor of hematopoietic cell kinase as a potential therapeutic agent for acute myeloid leukemia.
Roversi FM; Bueno MLP; da Silva JAF; Assis-Mendonça GR; Torello CO; Shiraishi RN; Pericole FV; Ferro KP; Duarte ASS; Rego EM; Saad STO
Cancer Immunol Immunother; 2022 Aug; 71(8):1909-1921. PubMed ID: 35039904
[TBL] [Abstract][Full Text] [Related]
18. Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes.
Alhan C; Westers TM; van der Helm LH; Eeltink C; Huls G; Witte BI; Buchi F; Santini V; Ossenkoppele GJ; van de Loosdrecht AA
Cytometry B Clin Cytom; 2014 May; 86(3):207-15. PubMed ID: 24474614
[TBL] [Abstract][Full Text] [Related]
19. The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with Azacitidine.
Miltiades P; Lamprianidou E; Vassilakopoulos TP; Papageorgiou SG; Galanopoulos AG; Kontos CK; Adamopoulos PG; Nakou E; Vakalopoulou S; Garypidou V; Papaioannou M; Hatjiharissi E; Papadaki HA; Spanoudakis E; Pappa V; Scorilas A; Tsatalas C; Kotsianidis I;
Clin Cancer Res; 2016 Apr; 22(8):1958-68. PubMed ID: 26700206
[TBL] [Abstract][Full Text] [Related]
20. Characterization of myelodysplastic syndromes hematopoietic stem and progenitor cells using mass cytometry.
Bachas C; Duetz C; van Spronsen MF; Verhoeff J; Garcia Vallejo JJ; Jansen JH; Cloos J; Westers TM; van de Loosdrecht AA
Cytometry B Clin Cytom; 2023 Mar; 104(2):128-140. PubMed ID: 35289472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
